ABVC BioPharma, Inc. (NASDAQ: ABVC) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, reporting total assets of $21,062,203, a 179% increase from $7,539,907 in 2024. The significant balance sheet expansion is largely attributed to strategic land acquisitions in Taiwan, with net property and equipment rising to $12,835,409 from $511,088 in the prior year.
As of December 31, 2025, the company reported property and equipment (net) of $12.84 million, operating lease right-of-use assets of $1.91 million, and long-term investments of $1.88 million. Management characterized the fiscal year as a structural strengthening of the balance sheet and asset foundation, positioning the company for long-term value creation.
ABVC's core drug programs have been licensed to subsidiary and related parties through a structure designed to transfer development risk while retaining economic participation. The CNS pipeline was licensed to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this model, these entities handle clinical development, reducing ABVC's direct cash burn exposure while preserving licensing economics and equity participation.
The company's strategic asset expansion in Taiwan includes two key properties. The Longtan District property in Taoyuan, spanning 5,995.41 square meters, was valued at $4.6 million as of December 31, 2025. This land is held as a strategic reserve with potential applications in healthcare, demonstration facilities, or supportive biotechnology infrastructure. The Puli Township property in Nantou, covering 69,230.90 square meters, was independently appraised at approximately $8.0 million in January 2026. ABVC plans to develop this site as a medicinal plant cultivation base, supporting pharmaceutical supply chain localization and agricultural-biotech integration, with projected annual output value estimated between $60,000 and $360,000.
Both land titles are pending government review and transition; the Longtan property is registered under a related party landholder pending regulatory approval, while the Puli title transfer is under government review. These acquisitions reflect ABVC's evolution from a purely IP-driven biotech company toward a hybrid model combining intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible physical assets.
ABVC BioPharma is a clinical-stage biopharmaceutical company with a pipeline of six drugs and one medical device, ABV-1701/Vitargus®, under development. The company utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal Phase III clinical trials through global partnerships.
Forward-looking statements in the press release are subject to risks and uncertainties detailed in the company's filings with the SEC, available at http://www.sec.gov.
